- Home
- LRHC vs APRE Comparison
LRHC vs APRE Comparison
Compare LRHC & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRHC
- APRE
- Stock Information
- Founded
- LRHC 2004
- APRE 2006
- Country
- LRHC United States
- APRE United States
- Employees
- LRHC N/A
- APRE N/A
- Industry
- LRHC
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LRHC
- APRE Health Care
- Exchange
- LRHC Nasdaq
- APRE Nasdaq
- Market Cap
- LRHC 8.4M
- APRE 8.3M
- IPO Year
- LRHC 2023
- APRE 2019
- Fundamental
- Price
- LRHC $5.42
- APRE $1.40
- Analyst Decision
- LRHC
- APRE Strong Buy
- Analyst Count
- LRHC 0
- APRE 1
- Target Price
- LRHC N/A
- APRE $20.00
- AVG Volume (30 Days)
- LRHC 10.6K
- APRE 110.0K
- Earning Date
- LRHC 11-19-2025
- APRE 11-07-2025
- Dividend Yield
- LRHC N/A
- APRE N/A
- EPS Growth
- LRHC N/A
- APRE N/A
- EPS
- LRHC N/A
- APRE N/A
- Revenue
- LRHC $78,037,079.00
- APRE $841,012.00
- Revenue This Year
- LRHC N/A
- APRE N/A
- Revenue Next Year
- LRHC N/A
- APRE N/A
- P/E Ratio
- LRHC N/A
- APRE N/A
- Revenue Growth
- LRHC 54.92
- APRE N/A
- 52 Week Low
- LRHC $4.33
- APRE $1.37
- 52 Week High
- LRHC $142.40
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- LRHC 31.93
- APRE 42.86
- Support Level
- LRHC $5.00
- APRE $1.43
- Resistance Level
- LRHC $7.04
- APRE $1.69
- Average True Range (ATR)
- LRHC 0.42
- APRE 0.10
- MACD
- LRHC -0.22
- APRE 0.00
- Stochastic Oscillator
- LRHC 15.85
- APRE 13.56
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.